Company news
ABVC BioPharma, Inc. news in 2023
ABVC BioPharma, Inc.'s news releases, calls and decks from 2023, newest first.
ABVC BioPharma Reports Third Quarter 2023 Financial and Operational Results
November 14, 2023
ABVC BioPharma Entered Into a Term Sheet to License Global Rights of CNS Drugs with the Indications of MDD and ADHD to AiBtl BioPharma at the Valuation of $667 Million
October 25, 2023
ABVC BioPharma Receives Taiwanese Patent for Its Treatment of Major Depressive Disorder (MDD)
October 8, 2023
ABVC BioPharma Provides Updates on ADHD Phase IIb Clinical Study
August 22, 2023
ABVC Executes Cooperation Agreement for Strategic Investments
August 16, 2023
ABVC BioPharma Regains Compliance With Nasdaq's Minimum Bid Price Requirement
August 9, 2023
ABVC Corporate Update and CEO's Letter to Shareholders
August 6, 2023
ABVC Announces the Approval of the Plan for GMP Production Facilities of Vitargus by Taiwan Science Park Administration
August 2, 2023
ABVC Signs a Term Sheet to Earn Licensing Fees of up to $20M and Royalties of 5-12% of Net Sales
July 31, 2023
ABVC BioPharma Announces Closing on $1.75 Million Registered Direct Offering
July 30, 2023
ABVC BioPharma Announces Pricing of $1.75 Million Registered Direct Offering
July 26, 2023
ABVC Signs Term Sheet to Acquire Real Estate Assets for Strategic Investments
July 25, 2023
ABVC BioPharma Announces Reverse Stock Split
July 23, 2023
ABVC BioPharma, Inc. Announces New CEO as It Targets Further Growth
June 25, 2023
ABVC BioPharma ADHD Phase II Part 2 Clinical Study First Subject Enrolled at UCSF
June 11, 2023
ABVC BioPharma Announces Collaboration With MerDury BioPharma for New Product Development and Commercialization
June 5, 2023
ABVC BioPharma Vitargus® Phase II Study Received Ethical Approval at Sydney Eye Hospital in Australia
May 21, 2023
ABVC BioPharma Receives US Patent Certificate of PDC-1421 for the Treatment of Major Depressive Disorder
May 3, 2023
ABVC BioPharma Announces Completion of Phase II Part 2 Clinical Study Site Initiation Visit at UCSF
April 25, 2023
ABVC BioPharma Provides ABV-1601 Update on Phase I Site Initiation Visit Conducted at Cedars-Sinai Medical Center (CSMC)
April 9, 2023
ABVC BioPharma Provides Vitargus Update on Phase II Site Initiation Visit Conducted at Ramathibodi Hospital in Thailand
April 5, 2023
ABVC BioPharma Announces Fiscal Year 2022 Financial and Operational Results
March 30, 2023
ABVC BioPharma Receives Registration Approval for Maitake Mushroom Dietary Supplement by the Taiwan Ministry of Health and Welfare
March 13, 2023
ABVC BioPharma Provides 2023 Pipeline Update
February 27, 2023
ABVC BioPharma Receives Australian TGA Approval to Initiate Phase II Study of Vitargus®
February 20, 2023
Decks in 2023
- Investor Presentation (June 2023)
Investor deck · 27 slides · Jun 9, 2023